Parexel

from Wikipedia, the free encyclopedia
PAREXEL International

logo
legal form Private
ISIN US6994621075
founding 1982
Seat Waltham, Massachusetts, United States

84+ locations in 51+ countries

management Chairman: Josef H. von Rickenbach

CEO: Jamie Macdonald

Number of employees 19,000
Branch Contract research institute

Services: clinical trial management, data management, medical writing, biostatistics, pharmacovigilance, regulatory advice

Website www.parexel.com
As of June 30, 2015

PAREXEL International is one of the world's leading service providers for biopharmaceutical research. It carries out clinical studies on behalf of customers from the pharmaceutical sector , thereby accompanying and accelerating drug approval . PAREXEL is the world's second largest contract research organization and has been involved in the development of approximately 95% of the 200 best-selling biopharmaceuticals on the market today . The company publishes the annual PAREXEL R&D Statistical Sourcebook, operates the PAREXEL Academy, and advises all top 50 biopharmaceutical and top 30 biotechnology companies.

PAREXEL was founded in 1982 by Josef von Rickenbach and the organic chemist Anne B. Sayigh. Originally, Japanese and German companies were to be advised on the FDA approval procedure. The company has grown organically over the years and through 40 acquisitions. Rickenbach established the culture and practice of PAREXEL based on the principles he experienced as a researcher at Schering-Plow in Lucerne.

In 1990 the company expanded internationally and established new business areas. In 1999 it had 4,500 employees and 45 branches. In the 2000s the number of employees grew to over 18,000. PAREXEL's advisory work and work on clinical studies have promoted the introduction of many well-known drugs and contributed to numerous success stories in modern pharmacology.

The company was acquired by private equity firm Pamplona Capital Management for approximately $ 5 billion. The deal was closed in September 2017.

Acquisitions

  • June 1996: PAREXEL takes over in various transactions:
    • Caspard Consultants , a contract research company based in Paris, and
    • Sitebase Clinical Systems, Inc., a provider of remote data entry technologies to improve the quality and timeliness of clinical trial data.
  • August 1996: PAREXEL takes over 1,008,304 of its own ordinary shares in various transactions
    • Lansal Clinical Pharmaceutics, Limited, a contract research company based in Israel, and
    • State and Federal Associates, Inc., a provider of medical marketing and related advisory services to the healthcare and pharmaceutical industries based in Washington, DC
  • March 1997: In various transactions, PAREXEL takes over a total of 210,000 common shares:
    • RESCON, Inc., a medical marketing company based in the Washington, DC area, and
    • Sheffield Statistical Services, Ltd., a UK based company specializing in biostatistical analysis.
  • November 1997: PAREXEL acquires essentially all of the assets of the Hayden Image Processing Group, a Colorado-based company that develops software for analyzing and measuring high-resolution medical image data. PAREXEL also announces the strategic collaboration with The IRIS Group SA , based in Belgium, a company specializing in intelligent optical character recognition technologies.
  • December 1997: PAREXEL acquires Kemper-Masterson, Inc, a Massachusetts-based company specializing in advising pharmaceutical, biotechnology, and medical device companies on FDA and other regulatory matters.
  • March 1998: PAREXEL takes over four companies:
    • PPS Europe Limited , hereinafter renamed PAREXEL MMS Europe Limited , a medical marketing company based in the UK, and Genesis Pharma Strategies Limited , a company serving the international pharmaceutical industry in marketing and clinical communication with doctors, for 113, $ 1 million in treasury common stock;
    • MIRAI BV , a full-service, pan-European contract research company based in the Netherlands, for $ 26 million in its own common stock;
    • LOGOS GmbH , a provider of regulatory services to pharmaceutical manufacturers, for $ 3.9 million in its own common stock.
  • March 1999: PAREXEL acquires Groupe PharMedicom SA , a French provider of post-regulatory services for pharmaceutical manufacturers, based in Paris and Orléans with around 70 employees, in exchange for around 199,600 of the company's common shares.
  • April 1999: Covance Inc. announced it would acquire competitor PAREXEL for $ 612.7 million in shares and merge the two drug discovery and development companies under the name Covance Parexel Inc., only to cancel the agreement two months later withdraw.
  • September 1999: PAREXEL acquires CEMAF SA , a clinical research and bioanalytical laboratory for phase I studies, based in Poitiers, France, for a cash deposit of approximately US $ 3 million.
  • September 2000: PAREXEL acquires a majority stake in FARMOVS, a bioanalysis laboratory and research company for clinical pharmacology based in Bloemfontein, South Africa, for approximately 3 million US dollars. A few weeks later, the company took over a Clinical Pharmacology Unit based in Northwick Park Hospital in Harrow, Great Britain, from the British pharmaceutical company GlaxoWellcome Inc.
  • July 2001: PAREXEL acquires Edyabe , a contract research company in Latin America with offices in Argentina and Brazil for approximately $ 1.6 million in cash.
  • October 2002: PAREXEL takes over Invantage Inc , a privately held company in Cambridge, USA, which provides software and services to pharmaceutical and biotechnology companies, including DataWeb Enterprise Edition. It is a web-based repository of potential clinical investigators in combination with an environment for decision support when introducing clinical trials.
  • October 2002: PAREXEL acquires Pracon & HealthIQ (a division of Excerpta Medica, then a subsidiary of Reed Elsevier plc), a provider of specialized sales and marketing services based in Reston and Orange, USA, for approximately $ 1.7 million in cash.
  • January 2003: PAREXEL acquires FWPS Group Limited , a software provider for clinical trial management systems in Birmingham, UK, for approximately $ 11.9 million in cash and stock.
  • March 2004: PAREXEL buys the remaining majority of the outstanding shares of 3Clinical Research AG , a clinical research organization with expertise in phase I and phase IIa proof-of-concept studies based in Berlin for 11.7 million US- Dollars in cash.
  • October 2004: PAREXEL acquires Integrated Marketing Concepts (IMC), a privately held company based in Whitehall, USA, a provider of professional marketing and communication services specializing in patient recruitment and retention for clinical trials, sales line management, teleservices, call center services, Realization, focus group and database management and market research.
  • July 2005: PAREXEL acquires Qdot Pharma , a Phase I and Phase IIa proof-of-concept clinical pharmacology company based in George, South Africa, for approximately $ 3 million plus additional payments of up to approximately 3 million US dollars contingent purchase price if Qdot meets certain predetermined financial targets by September 28, 2008.
  • August 2005: PAREXEL buys the remaining 2.2% of its IT subsidiary Perceptive Informatics Inc. for $ 4.8 million in cash.
  • October 2006: PAREXEL enters into a joint venture agreement with Synchron Research Services Private Limited (with a 75 percent participation by PAREXEL) under which Synchron will transfer its clinical research activities, based in Bangalore, India, to a newly formed organization, PAREXEL International Synchron Private Limited, transfers .
  • October 2006: PAREXEL acquires California Clinical Trials Medical Group, Inc. , and Behavioral and Medical Research, LLC , both headquartered in San Diego, USA, which provide a broad spectrum of Phase I - IV services across four clinical locations in California offer clinical trials for $ 65 million.
  • October 2007: PAREXEL takes over Apex International Clinical Research Co. Ltd (PAREXEL has held a minority stake since April 2003), a privately owned contract research company based in Taiwan, whose area of ​​activity is the People's Republic of China, Hong Kong, India, Taiwan, Singapore, Indonesia, South Korea, Malaysia, Thailand, which includes the Philippines, New Zealand, and Australia, for about $ 50.9 million.
  • August 2008: PAREXEL acquires ClinPhone plc , a provider of telephone and web-based systems used for clinical trials, headquartered in Nottingham, England, with 731 employees, for $ 182 million.
  • December 2012: PAREXEL takes over LIQUENT Inc., a global provider of regulatory information management solutions based in Horsham, USA, and further branches in Great Britain, Germany and India, with almost 300 employees, for around 72 million US dollars.
  • April 2013: PAREXEL acquires Heron Group , a life sciences consultancy providing commercialization services to biopharmaceutical companies, based in Luton, UK with offices in India, Sweden and the US, for up to $ 38.2 million .
  • July 2014: PAREXEL acquires ATLAS Medical Services , a provider of clinical research services in Turkey, the Middle East and North Africa, with headquarters in Istanbul and 35 employees.
  • October 2014: PAREXEL acquires ClinIntel Limited , a provider of clinical randomization and trial supply management services based in Crawley, UK.
  • April 2015: PAREXEL takes over Quantum Solutions India , a provider of outsourced safety management solutions (drug monitoring) with around 900 employees.
  • February 2016: PAREXEL takes over Health Advances LLC , an independent consultancy in the life sciences strategy sector with 120 employees.
  • September 2016: PAREXEL takes over ExecuPharm Inc , a global functional service provider with headquarters in King of Prussia, USA.

TGN1412 Clinical Study

Main article: TGN1412

In March 2006, a study carried out by PAREXEL on behalf of the now bankrupt biotech company TeGenero at Northwick Park Hospital in London showed severe inflammatory reactions and multiple organ failure in six healthy volunteers. The monoclonal antibody TGN1412, which was to be used to treat rheumatoid arthritis, multiple sclerosis or leukemia, was tested. The antibody was previously tested on animals, this was the first attempt in humans.

After TeGenero's insurance policy was unable to provide adequate compensation, PAREXEL was targeted by lawyers representing the injured volunteers. When the liable company then filed for bankruptcy, the volunteers' lawyers initiated legal proceedings against PAREXEL and the two parties who later entered into the talks. The results of this meeting were not published.

A documentary broadcast in the UK on September 28, 2006, featuring journalist Brian Deer on Channel 4's "Dispatches" series, was unclear about the existence of data TeGenero had prior to the Medicines and Healthcare products Regulatory study Agency (MHRA) should have submitted. It should have been pointed out whether TGN1412 was adequately tested in vitro in human blood. There were also concerns as to whether or not a safe dose for humans was being followed by TeGenero. However, the MHRA concluded that none of the companies involved could be held responsible for the outcome of the test and that the adverse events that occurred were most likely caused by an unforeseen effect of the antibody in the human body.

Individual evidence

  1. ↑ a b PAREXEL - our company: www.parexel.com .
  2. ↑ TOP PROS ´ TOP PICKS - PAREXEL puts drugs on trial: MoneyShow.com . ( moneyshow.com ).
  3. ↑ PAREXEL Biopharmaceutical Statistical Sourcebook 2014/2015: http://www.barnettinternational.com/Publications/Parexel-Biopharmaceutical/Statistical-Sourcebook-2014/2015 .
  4. ↑ Applied Clinical Trials Editorial Staff (April 13, 2015). "PAREXEL Academy Adds Programs for Students": http://www.appliedclinicaltrialsonline.com/parexel-academy-adds-programs-students .
  5. ↑ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MjQwNDc3fENoaWxkSUQ9LTF8VHlwZT0z&t=1 .
  6. ↑ Josef von Rickenbach - PAREXEL: https://www.bilanz.ch/people/josef-von-rickenbach-parexel .
  7. ↑ https://www.the-scientist.com/briefs/entrepreneur-briefs-62738 .
  8. ↑ Josef von Rickenbach - PAREXEL: https://www.bilanz.ch/people/josef-von-rickenbach-parexel .
  9. ↑ https://www.reuters.com/article/brief-pamplona-capital-management-comple/brief-pamplona-capital-management-completes-acquisition-of-parexel-idUSFWN1MA0SJ .
  10. ↑ a b PAREEL Form 10-K (1997): https://www.sec.gov/Archives/edgar/data/799729/0000950135-97-003994.txt .
  11. ↑ PAREXEL COMPLETES TWO ACQUISITIONS: https://www.prnewswire.co.uk/news-releases/parexel-completes-two-acquisitions-156113125.html . PRNNewswire UK.
  12. ↑ PAREXEL Announces Information Technology Investments: https://www.prnewswire.com/news-releases/parexel-announces-information-technology-investments-77414662.html . PRNewswire.
  13. ↑ PAREXEL Completes Acquisition of Kemper-Masterson, Inc: https://www.prnewswire.com/news-releases/parexel-completes-acquisition-of-kemper-masterson-inc-77745537.html . PRNewswire.
  14. ↑ PAREXEL Acquires Leading International Contract Marketing Services Company: https://www.prnewswire.com/news-releases/parexel-acquires-leading-international-contract-marketing-services-company-76938087.html . PRNewswire.
  15. ↑ PAREXEL Pays $ 148 Million For Three European Firms: https://www.wsj.com/articles/SB8888824026187500 . The Wall Street Journal. ISSN 0099-9660.
  16. ↑ PAREXEL Acquires Groupe Pharmedicom: https://www.prnewswire.com/news-releases/parexel-acquires-groupe-pharmedicom-73816747.html . PRNewswire.
  17. ↑ Covance says it is acquiring PAREXEL for $ 612 million: https://www.nytimes.com/1999/04/30/business/company-news-covance-says-it-is-acquiring-parexel-for-612-million .html . The New York Times.
  18. ↑ Covance, PAREXEL part: https://money.cnn.com/1999/06/25/deals/covance/ . CNN Money.
  19. ↑ PAREXEL Acquires the Phase I Clinical Research Business and Bioanalytical Laboratory of CEMAF SA: https://www.prnewswire.com/news-releases/parexel-acquires-the-phase-i-clinical-research-business-and-bioanalytical- laboratory-of-cemaf-sa-74407922.html . PRNewswire.
  20. ↑ PAREXEL Acquires Majority Interest in Clinical Pharmacology Research Business and Bioanalytical Laboratory in South Africa: https://www.prnewswire.com/news-releases/parexel-acquires-majority-interest-in-clinical-pharmacology-research-business-and -bioanalytical-laboratory-in-south-africa-74981577.html . PRNewswire.
  21. ↑ PAREXEL acquires Glaxo's UK pharmacology unit: https://www.drugdiscoveryonline.com/doc/parexel-acquires-glaxos-uk-pharmacology-unit-0001 . www.drugdiscoveryonline.com.
  22. ↑ PAREXEL International Enhances Presence in Latin America: https://www.prnewswire.com/news-releases/parexel-international-enhances-presence-in-latin-america-71522197.html . PRNewswire.
  23. ↑ Perceptive Informatics acquires Invantage: https://www.parexel.com/company/news-events/press-releases/2002/perceptive-informatics-acquires-invantage-inc .
  24. ↑ PAREXEL acquires Pracon & HealthIQ: https://www.bizjournals.com/boston/stories/2002/11/04/daily7.html . Boston Business Journal. American City Business Journals.
  25. ↑ Acquisitions and Impact of Restructuring and Other Charges: https://www.sec.gov/Archives/edgar/data/799729/000095013503004856/b47766pie10vk.txt . PAREXEL Form 10-K (2003).
  26. ↑ a b NOTE 18. Subsequent Events: https://www.sec.gov/Archives/edgar/data/799729/000095013505005299/b55585pie10vk.txt . PAREXEL Form 10-K 2005.
  27. ↑ PAREXEL acquires marketing firm: https://www.bizjournals.com/boston/blog/mass-high-tech/2004/10/parexel-acquires-marketing-firm.html . Boston Business Journal. American City Business Journals.
  28. ↑ PAREXEL buys out remaining minority interest in Perceptive Informatics: https://www.bizjournals.com/boston/blog/mass-high-tech/2005/08/parexel-buys-out-remaining-minority-interest.html . Boston Business Journal. American City Business Journals.
  29. ↑ PAREXEL establishes Presence in India: http://www.pharmaasia.com/2006/10/parexel-establishes-presence-in-india/ . pharmaasia.com. Contineo Media Pte Ltd (Singapore).
  30. ↑ PAREXEL Agrees to Acquire California Clinical Trials Medical Group, Inc., and Behavioral and Medical Research, LLC; Acquistion Adds West Coast Phase I Unit and Specialty Phase II - IV Clinical Research Services: https://www.edgemont.com/news/parexel-agrees-to-acquire-california-clinical-trials-medical-group-inc-and -behavioral-and-medical-research-llc / . www.edgemontcapital.com/. Edgemont Capital Partners.
  31. ↑ PAREXEL strengthens Asia-Pacific hand with Apex acquisition: http://www.pharmatimes.com/news/parexel_strengthens_asia-pacific_hand_with_apex_acquisition_991000 . pharmatimes.com. PharmaTimes Media Ltd.
  32. ↑ PAREXEL puts up $ 182M for UK firm ClinPhone: https://www.bizjournals.com/boston/blog/mass-high-tech/2008/06/parexel-puts-up-182m-for-uk-firm-clinphone .html . Boston Business Journal. American City Business Journals.
  33. ↑ PAREXEL announces acquisition of Liquent, Inc., and Updates Financial Guidance: https://www.prnewswire.com/news-releases/parexel-international-announces-acquisition-of-liquent-inc-and-updates-financial-guidance -184922131.html . PRNewswire. Cision Inc.
  34. ↑ PAREXEL acquires Heron Group in up to $ 38M Deal: https://www.genengnews.com/topics/drug-discovery/parexel-acquires-heron-group-in-up-to-38m-deal/ . Genetic Engineering & Biotechnology News. Mary Ann Liebert, Inc.
  35. ↑ PAREXEL taps Middle East, North Africa with Atlas acquisition: https://www.outsourcing-pharma.com/Article/2014/07/02/Parexel-taps-Middle-East-North-Africa-with-Atlas-acquisition . outsourcing-pharma.com. William Reed Business Media.
  36. ↑ PAREXEL acquires ClinIntel: https://www.cosmeticsbusiness.com/news/article_page/Parexel_acquires_ClinIntel/102253 . CosmeticsBusiness. HPCi Media Ltd.
  37. ↑ PAREXEL to tap additional pharmacovigilance services with QSI acquisition: https://www.outsourcing-pharma.com/Article/2015/03/26/Parexel-to-tap-additional-pharmacovigilance-services-with-QSI-acquisition . outsourcing-pharma.com. William Reed Business Media.
  38. ↑ PAREXEL moves to buy a pharma consulting firm: https://www.fiercebiotech.com/cro/parexel-moves-to-buy-a-pharma-consulting-firm . FierceBiotech.
  39. ↑ PAREXEL to acquire ExecuPharm: https://www.contractpharma.com/contents/view_breaking-news/2016-09-27/parexel-to-acquire-execupharm . Contract Pharma. Rodman Media.
  40. ↑ Drugs trial men seriously ill: http://news.bbc.co.uk/2/hi/uk_news/england/london/4808836.stm . BBC News.
  41. ↑ When drug trials go horribly wrong: www.iht.com/articles/2006/04/07/news/drug.php . The International Herald Tribune.
  42. ↑ Does PAREXEL want to settle? TeGenero Litigation: http://www.clinpage.com/article/tegenero_litigation/C7 . ClinPage.
  43. ↑ Window is open for compensation in TGN1412: http://www.pharmatimes.com/ClinicalNews/article.aspx?id=10534 . PharmaTimes.
  44. ↑ PAREXEL issues statement regarding TeGenero clinical trial: http://www.firstwordpharma.com/node/155450#axzz3nhMIqzxb .
  45. ↑ Clinical Trial Final Report, MHRA - archived: https://web.archive.org/web/20061206104242/http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&useSecondary=true&ssDocName=CON2023822&ssTargetNodeId=389 . MHRA.